All In Biotech

Drug Trial Radar · NCT01743729

A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Currently Using Artificial Tears (OPUS-2)

Last checked: Nov 20, 2026Latest source record: Jun 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

720

Actual

Start

Dec 7, 2012

Primary completion

Oct 1, 2013

Study completion Oct 1, 2013

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Dec 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and efficacy of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye.

Conditions

  • Dry Eye Disease

Interventions

  • LifitegrastDrug

    Lifitegrast Ophthalmic Solution 5.0%

  • PlaceboDrug

    Placebo for Lifitegrast Ophthalmic Solution 5.0%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 84Time frame: Baseline to Day 84
  2. Change From Baseline in Eye Dryness Score (Visual Analogue Scale) to Day 84Time frame: Baseline to Day 84

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • OPUS-2 Investigational Site

    Artesia, California

  • OPUS-2 Investigational Site

    Hemet, California

  • OPUS-2 Investigational Site

    Lancaster, California

  • OPUS-2 Investigational Site

    Mission Hills, California

  • OPUS-2 Investigational Site

    Montebello, California

  • OPUS-2 Investigational Site

    Newport Beach, California

  • OPUS-2 Investigational Site

    Petaluma, California

  • OPUS-2 Investigational SIte

    Rancho Cordova, California

  • OPUS-2 Investigational Site

    Danbury, Connecticut

  • OPUS-2 Investigational Site

    Fort Myers, Florida

  • OPUS-2 Investigational Site

    Hoffman Estates, Illinois

  • OPUS-2 Investigational Site

    Indianapolis, Indiana

  • OPUS-2 Investigational Site

    New Albany, Indiana

  • OPUS-2 Investigational Site

    Lexington, Kentucky

  • OPUS-2 Investigational Site

    Saint Paul, Minnesota

  • OPUS-2 Investigational Site

    Chesterfield, Missouri

  • OPUS-2 Investigational Site

    Des Peres, Missouri

  • OPUS-2 Investigational Site

    Independence, Missouri

  • OPUS-2 Investigational Site

    Kansas City, Missouri

  • OPUS-2 Investigational Site

    Washington, Missouri

  • OPUS-2 Investigational Site

    New York, New York

  • OPUS-2 Investigational Site

    New York, New York

  • OPUS-2 Investigational Site

    Wantagh, New York

  • OPUS-2 Investigational Site

    Cleveland, Ohio

  • OPUS-2 Investigational Site

    Philadelphia, Pennsylvania

  • OPUS-2 Investigational Site

    Houston, Texas

  • OPUS-2 Investigational Site

    Houston, Texas

  • OPUS-2 Investigational Site

    League City, Texas

  • OPUS-2 Investigational Site

    San Antonio, Texas

  • OPUS-2 Investigational Site

    San Antonio, Texas

  • OPUS-2 Investigational Site

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.